Company registration number 09910964 (England and Wales)
CENOTE PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
3 Acorn Business Centre
Northarbour Road
Cosham
Portsmouth
Hampshire
United Kingdom
PO6 3TH
CENOTE PHARMA LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2
Notes to the financial statements
3 - 5
CENOTE PHARMA LIMITED
COMPANY INFORMATION
- 1 -
Directors
Mr G Buckley
Mr R Condon
Mr J May
Company number
09910964
Registered office
102 High Street
Godalming
Surrey
United Kingdom
GU7 1DS
Accountants
TC Group
3 Acorn Business Centre
Northarbour Road
Cosham
Portsmouth
Hampshire
United Kingdom
PO6 3TH
CENOTE PHARMA LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 2 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
3
4,500
4,500
Net current assets
4,500
4,500
Capital and reserves
Called up share capital
4
4,500
4,500

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 26 June 2026 and are signed on its behalf by:
Mr G Buckley
Director
Company registration number 09910964 (England and Wales)
CENOTE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

Cenote Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 102 High Street, Godalming, Surrey, United Kingdom, GU7 1DS.

 

On 7 March 2024 the company was acquired by Aspire Pharma Limited, a UK registered company. On the same date the net assets of the company were hived up to Aspire Pharma Limited and moving forward the company will remain dormant. The company's financial reporting period was subsequently shortened to mirror that of it's new parent entity.

1.1
Reporting period

These financial statements present the year ended 31 December 2025, whilst the comparatives present the period from 7 March 2024 to 31 December 2024.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

CENOTE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

1.5
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2
Employees

The average monthly number of persons employed by the company during the year was:

December
March
2025
2024
Number
Number
Total
0
0
3
Debtors
2025
2024
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
4,500
4,500
4
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A Ordinary of £1 each
1,500
1,500
1,500
1,500
B Ordinary of £1 each
1,500
1,500
1,500
1,500
C Ordinary of £1 each
1,500
1,500
1,500
1,500
4,500
4,500
4,500
4,500
CENOTE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 5 -
5
Related party transactions
Transactions with related parties

The company has taken exemption under Section 33.1A of FRS102 from disclosing transactions between wholly owned members of the same group.

6
Parent company

The company is wholly owned by Aspire Pharma Limited, a company registered in England. The smallest company within which the accounts are consolidated is APHL 2 Limited.

 

The ultimate controlling party is considered to be H.I.G Europe Middle Market LBO Fund L.P. (Cayman), a company incorporated in the Cayman Islands.

2025-12-312025-01-01falsefalsetrueCCH SoftwareCCH Accounts Production 2026.200No description of principal activityMr G BuckleyMr R CondonMr J May099109642025-01-012025-12-3109910964bus:Director12025-01-012025-12-3109910964bus:Director22025-01-012025-12-3109910964bus:Director32025-01-012025-12-3109910964bus:RegisteredOffice2025-01-012025-12-31099109642025-12-3109910964core:WithinOneYear2025-12-3109910964core:WithinOneYear2024-12-31099109642024-12-3109910964core:ShareCapital2025-12-3109910964core:ShareCapital2024-12-3109910964core:ShareCapitalOrdinaryShareClass12025-12-3109910964core:ShareCapitalOrdinaryShareClass12024-12-3109910964core:ShareCapitalOrdinaryShareClass22025-12-3109910964core:ShareCapitalOrdinaryShareClass22024-12-3109910964core:ShareCapitalOrdinaryShareClass32025-12-3109910964core:ShareCapitalOrdinaryShareClass32024-12-3109910964core:ShareCapitalOrdinaryShares2025-12-3109910964core:ShareCapitalOrdinaryShares2024-12-31099109642024-03-072024-12-3109910964core:CurrentFinancialInstruments2024-12-3109910964bus:OrdinaryShareClass12025-01-012025-12-3109910964bus:OrdinaryShareClass22025-01-012025-12-3109910964bus:OrdinaryShareClass32025-01-012025-12-3109910964bus:OrdinaryShareClass12025-12-3109910964bus:OrdinaryShareClass12024-12-3109910964bus:OrdinaryShareClass22025-12-3109910964bus:OrdinaryShareClass22024-12-3109910964bus:OrdinaryShareClass32025-12-3109910964bus:OrdinaryShareClass32024-12-3109910964bus:AllOrdinaryShares2025-12-3109910964bus:AllOrdinaryShares2024-12-3109910964bus:EntityNoLongerTradingButTradedInPast2025-01-012025-12-3109910964bus:PrivateLimitedCompanyLtd2025-01-012025-12-3109910964bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3109910964bus:FRS1022025-01-012025-12-3109910964bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3109910964bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP